Scott Shields Emerson
Scott Shields Emerson is an American biostatistician and emeritus professor of the University of Washington.[1][2]
Emerson was a professor of biostatistics[3] at the University of Washington in the School of Public Health's department of biostatistics[4] from 1999[5] to 2017.[6][7] Emerson worked on randomized controlled trial design.[8][9] Emerson has been part of advisory committees for the Food and Drug Administration,[10][11] including on work related to Aduhelm.[12][13]
Schooling[edit]
Emerson studied at the University of Virginia and the University of Washington.
References[edit]
- ^ Joseph, Andrew (June 8, 2021). "Member of FDA's expert panel resigns over controversial Alzheimer's therapy approval".
- ^ "Aducanumab Data Finally Published, but Alzheimer's Experts Spot Problems". www.medpagetoday.com. March 23, 2022.
- ^ "FDA Committee Expresses Concerns about Promising Alzheimer's Drug". Time.
- ^ "Emerson Statistics | R information". www.uwintrostats.org.
- ^ Scott Shields Emerson. "Curriculum Vitae" (PDF). emersonstatistics.com.
- ^ "Scott S. Emerson, M.D., Ph.D. | Home Page". faculty.washington.edu.
- ^ "| UW School of Public Health". sph.washington.edu.
- ^ Emerson, Scott S.; Kittelson, John M.; Gillen, Daniel L. (December 10, 2007). "Frequentist evaluation of group sequential clinical trial designs". Statistics in Medicine. 26 (28): 5047–5080. doi:10.1002/sim.2901. PMID 17573678. S2CID 16825572.
- ^ "RCTdesign.org : Methods and Software for Clinical Trials". rctdesign.org.
- ^ "Advisory Committee Again Urges FDA to Vote No on Aducanumab | ALZFORUM". www.alzforum.org.
- ^ Herman, Bob (July 27, 2021). "Biogen pulled Aduhelm paper after JAMA demanded edits". Axios.
- ^ "JAMA Paper Withdrawal Adds One More Layer to Aduhelm Controversy". BioSpace.
- ^ Review, The Regulatory (July 6, 2021). "Regulatory Reactivity in FDA's Approval of Aduhelm | The Regulatory Review". www.theregreview.org.
  | This biography of an American academic is a stub. You can help Wikipedia by expanding it. |